Your cousin is in a hospital bed on oxygen after COVID. A relative overseas texts that “thymosin alpha-1 raises immune cells in COVID” and sends a screenshot of a research-catalog vial. The family group chat asks whether someone should bring that up with the floor team today.
There was a small open-label pilot. It nudged one blood-cell count in people on low-flow oxygen. It did not prove faster recovery, and it did not test a catalog peptide.
What the Brown University COVID pilot found
Shehadeh and colleagues reported a prospective, open-label, randomized pilot in The Journal of Infectious Diseases in 2023. Forty-nine hospitalized adults with COVID, low oxygen, and low lymphocyte counts were compared on thymalfasin (synthetic thymosin alpha-1) plus usual care versus usual care alone. The trial is recorded as NCT04487444.
Among people who started on low-flow oxygen, treated patients had roughly four times more CD4 T cells by day five than on day one, a difference that reached statistical significance versus controls. Clinical recovery rates looked a little higher on active drug for both low-flow and high-flow groups, but those differences were not significant. Nine serious adverse events in treated patients were judged unrelated to thymosin alpha-1.
The authors said thymosin alpha-1 may have a role in this narrow hospital setting. They did not claim a new standard of care, and the study was not blinded.
How this differs from other thymosin alpha-1 files
Everyday Brief has covered overseas Zadaxin history, the large TESTS sepsis trial that found no 28-day survival benefit, and a 2010 metastatic melanoma combination study. Hospital COVID with lymphocytopenia is a fourth clinical question. None of those papers evaluated a research-catalog listing marketed for everyday immune support.
MedlinePlus pages on COVID still emphasize vaccination, early medical care for warning signs, and clinician-directed hospital protocols. A family screenshot is not a protocol.
What to ask the inpatient team
Ask which oxygen plan, antivirals, steroids, or other measures the hospital is already using, and what the monitoring plan is for lymphocytes and infection. If thymosin alpha-1 comes up, ask whether the relative means this open-label pilot, an overseas licensed product, or a catalog listing, and whether any trial is open at that hospital.
A CD4 bump on day five can sound dramatic in a group chat. In this pilot it was a secondary lab signal, not a proven shortcut out of the ward.
Not medical advice.
Sources
- Shehadeh F et al. A Pilot Trial of Thymalfasin (Thymosin-alpha-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to COVID-19. J Infect Dis, 2023 (PubMed)
- Full text: Shehadeh et al. 2023 thymalfasin COVID pilot (PubMed Central)
- ClinicalTrials.gov: NCT04487444
- MedlinePlus: COVID-19 (Coronavirus Disease 2019)
Related reading
- Zadaxin overseas history versus U.S. catalog screenshots
- TESTS phase 3: no 28-day survival benefit in sepsis
- The 2010 metastatic melanoma combination study in context
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-15 PT. Not medical advice.